Natural history of central sparing in geographic atrophy secondary to non-exudative age-related macular degeneration
- PMID: 33361441
- PMCID: PMC8813644
- DOI: 10.1136/bjophthalmol-2020-317636
Natural history of central sparing in geographic atrophy secondary to non-exudative age-related macular degeneration
Abstract
Background: The macular central 1 mm diameter zone is crucial to patients' visual acuity, but the long-term natural history of central sparing in eyes with geographic atrophy (GA) is unknown.
Methods: We manually segmented GA in 210 eyes with GA involving central 1 mm diameter zone (mean follow-up=3.8 years) in the Age-Related Eye Disease Study. We measured the residual area in central 1 mm diameter zone and calculated central residual effective radius (CRER) as square root of (residual area/π). A linear mixed-effects model was used to model residual size over time. We added a horizontal translation factor to each data set to account for different durations of GA involving the central zone.
Results: The decline rate of central residual area was associated with baseline residual area (p=0.008), but a transformation from central residual area to CRER eliminated this relationship (p=0.51). After the introduction of horizontal translation factors to each data set, CRER declined linearly over approximately 13 years (r2=0.80). The growth rate of total GA effective radius was 0.14 mm/year (95% CI 0.12 to 0.15), 3.7-fold higher than the decline rate of CRER (0.038 mm/year, 95% CI 0.034 to 0.042). The decline rate of CRER was 53.3% higher in eyes with than without advanced age-related macular degeneration in the fellow eyes at any visit (p=0.007).
Conclusions: CRER in eyes with GA declined linearly over approximately 13 years and may serve as an anatomic endpoint in future clinical trials aiming to preserve the central zone.
Keywords: degeneration; macula; retina; treatment medical.
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: EML, Scientific advisory board—Apellis Pharmaceuticals, Galimedix, Retrotope; Consultant—Genentech/Roche, Novartis, Gemini Therapeutics, Allegro Ophthalmics; Research funding through her University—Roche, Apellis Pharmaceuticals, LumiThera; CAT, Royalties through her university—Alcon and Hemosonics; LVDP, Consultant—Astellas Institute for Regenerative Medicine, LambdaVision; Scientific advisory board—Tissue Regeneration Sciences; Scientific and clinical advisors—CavTheRx.
Figures
References
-
- Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014;2:e106–e16. - PubMed
-
- Lindner M, Boker A, Mauschitz MM, Gobel AP, Fimmers R, Brinkmann CK, et al. Directional kinetics of geographic atrophy progression in age-related macular degeneration with foveal sparing. Ophthalmology. 2015;122:1356–65. - PubMed
-
- Shen L, Sun M, Ahluwalia A, Young B, Park M, Toth C, et al. Relationship of topographic distribution of geographic atrophy to visual acuity in dry age-related macular degeneration. Manuscript submitted for publication. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous